Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-one ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $610.95.
PRAX has been the subject of a number of analyst reports. Wells Fargo & Company reissued a "positive" rating and issued a $362.00 price target (up from $323.00) on shares of Praxis Precision Medicines in a report on Friday, August 7th. Royal Bank Of Canada restated an "outperform" rating and issued a $462.00 target price (up from $449.00) on shares of Praxis Precision Medicines in a report on Friday, August 7th. Piper Sandler reaffirmed an "overweight" rating on shares of Praxis Precision Medicines in a research note on Monday, July 13th. Needham & Company LLC reiterated a "buy" rating and set a $582.00 price target on shares of Praxis Precision Medicines in a report on Thursday, September 24th. Finally, Wall Street Zen raised shares of Praxis Precision Medicines from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th.
Check Out Our Latest Report on PRAX
Praxis Precision Medicines Stock Performance
PRAX opened at $248.24 on Friday. The company has a market cap of $6.93 billion, a price-to-earnings ratio of -19.20 and a beta of 2.79. Praxis Precision Medicines has a one year low of $154.45 and a one year high of $392.70. The business's fifty day moving average is $324.07 and its two-hundred day moving average is $318.85.
Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($2.87) earnings per share for the quarter, beating analysts' consensus estimates of ($3.67) by $0.80. On average, analysts predict that Praxis Precision Medicines will post -13.90 EPS for the current fiscal year.
Institutional Trading of Praxis Precision Medicines
A number of hedge funds have recently bought and sold shares of the company. Avior Wealth Management LLC purchased a new stake in Praxis Precision Medicines in the 3rd quarter valued at about $227,000. GAMMA Investing LLC grew its holdings in Praxis Precision Medicines by 30.1% in the third quarter. GAMMA Investing LLC now owns 432 shares of the company's stock valued at $126,000 after purchasing an additional 100 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Praxis Precision Medicines during the second quarter worth approximately $38,000. Nykredit A S acquired a new position in Praxis Precision Medicines during the second quarter worth approximately $261,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Praxis Precision Medicines during the second quarter worth approximately $2,698,000. Institutional investors and hedge funds own 67.84% of the company's stock.
About Praxis Precision Medicines
(
Get Free Report)
Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company uses insights from human genetics, neuroscience and its Cerebrum™ platform to identify and advance medicines for conditions in which existing treatment options may be limited.
Praxis' pipeline has included investigational treatments for epilepsies and other neurological disorders, including developmental and epileptic encephalopathies, essential tremor and movement-related conditions.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Praxis Precision Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.
While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
